repeated chemotherapy, but whose disease activity finally subsided after autologous peripheral blood stem cell transplantation (PBSCT) following high-dose combination A 30-month-old boy with hemophagocytic lymphohistiocytosis (HLH) received an autologous peripheral chemotherapy including etoposide (VP16). blood stem cell transplant (PBSCT) following high-dose chemotherapy. He presented with hemophagocytic syndrome (HPS) at 6 months of age, but relapsed despite Case report the repeated administration of prednisolone, VP-16, cyclosporin A (CsA), and other cytotoxic agents. PBSC A 6-month-old boy was transferred to our hospital because of respiratory distress and high fever. He was the first-born were obtained using combination chemotherapy with etoposide (VP16, 450 mg/m 2 ), doxorubicin (70 mg/m 2 ), child of healthy nonsanguineous parents. The perinatal period had been uneventful. There was no family history of vincristine (2 mg/m 2 ) and cyclophosphamide (CY, 1200 mg/m 2 ). 2.7 ؋ 10 5 /kg CFU-GM PBSC were trans-HLH. He was treated in hospital because of a skin eruption and cellulitis in the lower leg. Plantar indurations emerged planted after similar high-dose VP16 preconditioning used for allogeneic BMT for HLH. The boy continues with expansion of erythema. On day 16 of hospitalization, he became lethargic and dyspneic with prolonged high to remain in complete remission 30 months after PBSCT while receiving low-dose PSL/CsA therapy.
/l, Hb 8.8 g/dl and a platelet count of 213 ϫ hepatosplenomegaly, cytopenias, disseminated intravascu-10 9 /l. The rapid decrease in platelets required daily translar coagulopathy (DIC), and increased hemophagocytosingfusions. Blood chemistry was as follows: albumin 2.9 g/dl; macrophages. [1] [2] [3] There are two major clinical forms of aspartate aminotransferase, 11 010 IU/l; alanine amino-HLH; one is associated with infectious agents such as the transferase, 2470 IU/l; lactate dehydrogenase (LDH), Epstein-Barr (EB) virus (infection-associated HPS:
84 100 IU/l; ␥-glutamyl transpeptidase, 348 IU/l; triglycer-IAHS), 4, 5 while the other is associated with a genetic abnoride, 646 mg/dl; total cholesterol, 118 mg/dl; and total bilimality (familial hemophagocytic lymphohistiocytosis: rubin, 2.6 ml/dl, with 2.0 mg/dl of direct bilirubin. Serum FHL). 6 Diagnosis and management of HLH in infancy is levels of ferritin and lysozyme were 139 722 ng/ml, and quite difficult because it requires chemotherapy and leads 13.4 g/ml, respectively. C-reactive protein was 5.4 mg/dl. to a fatal course mimicking malignancy-associated HPS Coagulation studies indicated DIC: prothrombin time, (MAHS) or malignant histiocytosis. /day for 3 consecutive days) and prednisolone (PSL, 2 mg/kg) led to a clinical improvement paralleled with a prompt decrease in serum cytokine levels (soluble interleukin-2 receptor: sIL-2R 10 400 → 2150 U/ml, tumour necrosis factor-␣: TNF 60 → Ͻ5 pg/ml, interferon-␥ 44.8 → 0.9 U/ml).
7 Despite the development of pleural and subdural effusions, he achieved remission during PSL and VP16 therapy. Fever and erythema multiforme-like eruptions recurred at 5 /kg CFU-GM PBSC. The hematological recovery after PBSCT was satisfactory, in that WBC increased more than 1.0 ϫ fever, skin eruption, and liver dysfunction (ASL 321 U/ml, 10 9 /l within 11 days, platelets recovered to over 50 ϫ 10 9 /l within 8 days,
ALT 508 U/ml, LDH 823 U/ml) re-emerged with seizures.
and reticulocytes had increased more than 1% by day 13 following
The intermittent administration of VP16 (100 mg/m (Table 1) . During bone marrow recovery after this regimen, peripheral blood mononuclear total doses of VP16 and anthracycline during the entire treatment course were 9515 mg/m 2 , and 230 mg/m 2 , cells (PBMC) were collected by means of apheresis using a blood cell separator (Cobe Spectra, Cobe Laboratory, respectively. The low-dose PSL/CsA therapy was discontinued at 5 years of age. He has developed normally without Lakewood, CO, USA).
8 Recombinant human granulocyte colony-stimulating factor (rhG-CSF 100 g/m 2 ) was any adverse effects. administered to facilitate stem cell mobilization. This regimen safely yielded 3.7 ϫ 10 5 /kg CFU-GM peripheral blood stem cells (PBSC). Following an additional course of this Discussion chemotherapy, and myeloablative conditioning with busulfan (16 mg/kg), CY (120 mg/kg) and high-dose VP16 Infant HLH usually leads to a rapid deterioration without any response to supportive therapy. 9 Chemotherapy com-(75 mg/kg), he was transplanted with 2.7 ϫ 10 5 /kg CFU-GM, PBSC (Figure 1 ). After PBSCT, the WBC count fell prising VP16, PSL and intrathecal methotrexate 10 has been used to treat conditions such as FHL which have taken an to a nadir of 0.26 ϫ 10 9 /l with agranulocytosis, but recovered to more than 1.0 ϫ 10 9 /l within 11 days of transplanaggressive course during early infancy. Hypercytokinemia derived from T cell activation apparently accounts for the tation. The platelet count decreased to 19 ϫ 10 9 /l at day 6, but recovered to over 50 ϫ 10 9 /l within 8 days. The retitypical biological manifestations of HPS. However, the cytokine profile does not differentiate FHL from acquired culocyte count had increased more than 1% by day 13 following PBSCT. No serious complications occurred during HPS. 4, 11, 12 Virus infections cannot serve as useful criteria for distinguishing IAHS as an entity separate from FHL. 13 the rapid hematological recovery. CsA (5 mg/kg) and lowdose PSL (0.3 mg/kg) were effective for the treatment of Although this infant had no family history of HLH and suffered infection at the clinical onset, the relapsing and erythematous lesions transiently appearing 4 months after resistant course with a constellation of findings such as fever, DIC, skin eruptions, and central nervous system Table 1 The EVAC regimen for preconditioning of PBSC harvest involvement stresses the diagnosis of sporadic FHL. [1] [2] [3] VP16 is currently the most effective drug for the treat- 
